Susquehanna Fundamental Investments, LLC Abb Vie Inc. Transaction History

Susquehanna Fundamental Investments, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$132.51 - $164.9 $6.79 Million - $8.45 Million	-51,269 Reduced 73.74%	18,259 $2.46 Million
Q1 2023 May 16, 2023	SELL	$144.61 - $166.54 $4.04 Million - $4.65 Million	-27,948 Reduced 28.67%	69,528 $11.1 Million
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $3.87 Million - $4.64 Million	27,948 Added 40.2%	97,476 $15.8 Million
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $9.33 Million - $10.7 Million	69,528 New	69,528 $9.33 Million
Q2 2020 Aug 14, 2020	SELL	$73.37 - $98.18 $3.86 Million - $5.16 Million	-52,549 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$64.5 - $97.79 $1.7 Million - $2.57 Million	26,299 Added 100.19%	52,549 $4 Million
Q4 2019 Feb 14, 2020	SELL	$72.13 - $90.25 $295,733 - $370,025	-4,100 Reduced 13.51%	26,250 $2.32 Million
Q3 2019 Nov 14, 2019	SELL	$62.98 - $75.72 $2.82 Million - $3.39 Million	-44,750 Reduced 59.59%	30,350 $2.3 Million
Q2 2019 Aug 14, 2019	BUY	$65.7 - $83.98 $52,560 - $67,184	800 Added 1.08%	75,100 $5.46 Million
Q1 2019 May 15, 2019	BUY	$77.14 - $90.79 $5.73 Million - $6.75 Million	74,300 New	74,300 $5.99 Million
Q4 2018 Feb 14, 2019	SELL	$77.85 - $96.01 $973,124 - $1.2 Million	-12,500 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$88.91 - $98.84 $2.63 Million - $2.93 Million	-29,600 Reduced 70.31%	12,500 $1.18 Million
Q2 2018 Aug 14, 2018	SELL	$89.78 - $106.23 $314,230 - $371,805	-3,500 Reduced 7.68%	42,100 $3.9 Million
Q1 2018 May 15, 2018	BUY	$92.01 - $123.21 $4.2 Million - $5.62 Million	45,600 New	45,600 $4.32 Million

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.